The efficacy and safety of microwave ablation in patients with retroperitoneal metastases. (3rd October 2018)

• Record Type: Journal Article
• Authors: Wei, Zhigang; Ye, Xin; Yang, Xia; Zheng, Aimin; Huang, Guanghui; Dong, Shenming; Li, Wenhong; Wang, Jiao; Han, Xiaoying; Meng, Min; Ni, Yang
• Is Part Of: International journal of hyperthermia. Volume 34:Number 7(2018)
• Page Start: 1053
• Page End: 1060
• Publication Date: 2018-10-03
• Subjects: Microwave ablation -- retroperitoneal metastases -- computed tomography -- carcinoma -- visual analogue scale -- survival; Thermotherapy -- Periodicals; 615.832
• DOI: 10.1080/02656736.2017.1390788
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: Background: Retroperitoneal metastases are common, and most present with symptoms; however, treatments for this condition are limited. This retrospective study verified the efficacy and safety of microwave ablation (MWA) in retroperitoneal metastases patients. Methods: Patients with pathologically confirmed malignant carcinoma and imaging showing retroperitoneal metastases were enrolled and underwent MWA. The end-points included objective response rate, time to local progression (TTLP), overall survival, visual analogue scale (VAS) score, dose of morphine pre- and post-ablation and complications. Results: Twenty-three patients were enrolled. The mean tumour diameter was 3.6 cm. Altogether, 29 tumour sites in 23 patients were ablated during 23 procedures; technical success was achieved in all 23 patients. The objective response and disease control rates were 95.7% and 100.0%, respectively. The mean TTLP and median OS were 22.8 months (95% CI: 16.1–29.6 months) and 10.6 months (95% CI: 7.4–13.8 months), respectively. In 13 patients with symptoms, the VAS values before ablation and 48 h, 1 month, 2 months, 3 months and 6 months after ablation were 5.38, 2.77 ( p = 0.015), 2.15 ( p = 0.001), 2.17 ( p = 0.001), 1.40 ( p = 0.000) and 1.71 ( p = 0.006), respectively. The corresponding morphine doses were 76.9 mg, 70.7 mg ( p = 0.584), 50.7 mg ( p = 0.031), 55.0 mg ( p = 0.097), 46.0 mg ( p = 0.057) and 40.0 mg ( p = 0.363), respectively. No ablation-associated mortality was observed. Major complications, minor complications and adverse events were observed in eight (34.8%), five (21.7%) and four (17.4%) patients, respectively. Conclusion: MWA for the treatment of retroperitoneal metastases was effective and the complications were common.